乳腺癌HER-2低表达人群的靶向治疗新选择研究进展  

Research progress on new targeted therapy options for people with low HER-2expression in breast cancer

作　　者：冯梓航 李南林 温鑫鑫 FENG Zihang;LI Nanlin;WEN Xinxin(Department of Vascular and Endocrine Surgery,Xijing Hospital,Air Force Military Medical University,Xi'an 710032,China;No.6th Cadet,College of Basic Medical Sciences,Air Force Medical University,Xi'an 710032,China)

机构地区：[1]空军军医大学西京医院血管内分泌外科,陕西西安710032 [2]空军军医大学基础医学院学员六大队,陕西西安710032

出　　处：《中华肿瘤防治杂志》2023年第9期557-563,共7页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的对人表皮生长因子受体2(HER-2)低表达乳腺癌的临床特征、抗体偶联药物(antibody drug conjugates,ADCs)在HER-2低表达人群的治疗进展进行总结。方法以“HER-2 low breast cancer、antibody drug conjugates”为英文关键词在PubMed数据库进行检索,检索时间为自建库至2022年12月。纳入标准:(1)HER-2低表达乳腺癌的生物学和临床特征;(2)ADCs药物的临床前试验和临床试验。排除标准:(1)个案报道;(2)重复的临床试验。最终纳入50篇文献。结果随着ADCs药物临床数据的不断公布,HER-2低表达乳腺癌的概念逐渐被重视。HER-2低表达乳腺癌有望成为一个全新的治疗亚型。以T-Dxd为代表的ADCs药物,包括Trastuzumab-emtansine、Trastuzumab-deruxtecan、Trastuzumab-Duocarmazine、ARX-788、XMT-1522、MEDI4276、A166和MRG002已经在HER-2低表达乳腺癌人群中展示出较好的疗效,相信新型ADCs在不久的未来能够成为HER-2低表达乳腺癌人群的治疗新选择。结论以T-Dxd为代表的新型ADCs的不断问世将成为HER-2低表达乳腺癌人群的治疗新选择,并改善该人群的预后。Objective To summarize the clinical characteristics of breast cancer with low expression of human epidermal growth factor receptor 2(HER-2),and the progress of antibody coupled drugs(ADCs)in the treatment of people with low expression of HER-2.Methods The key words of"HER-2low breast cancer,antibody drug conjuates"were searched in PubMed database from the establishment of the database to December 2022.Inclusion criteria:(1)Biological and clinical characteristics of breast cancer with low HER-2expression;(2)Preclinical and clinical trials of ADC drugs.Exclusion criteria:(1)Case report;(2)Repeated clinical trials.Finally,50articles were included.Results With the continuous publication of clinical data of ADC drugs,the concept of HER-2low expression breast cancer has been gradually taken seriously.The low expression of HER-2in breast cancer is expected to become a new therapeutic subtype.ADC drugs represented by Trastuzumab-deruxtecan(T-Dxd),including Trastuzumab emtansine,Trastuzumab deruxtecan,Trastuzumab Duocarmazine,ARX-788,XMT-1522,MEDI4276,A166,and MRG002,have shown superior efficacy in HER-2low expression breast cancer populations.It is believed that new ADCs can become new treatment options for HER-2low expression breast cancer populations in the near future.Conclusion The emerging of new ADCs represented by T-Dxd will become a new treatment option for people with HER-2low expression breast cancer,and improve the prognosis of this population.

关 键 词：人表皮生长因子受体2 乳腺癌 抗体偶联药物 T-Dxd 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]